$345 Million is the total value of Rhenman & Partners Asset Management AB's 84 reported holdings in Q4 2014. The portfolio turnover from Q3 2014 to Q4 2014 was 42.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALKS | Sell | Alkermes Plc | $8,374,000 | -26.6% | 143,000 | -46.2% | 2.43% | -27.3% |
| ALXN | Sell | Alexion Pharmaceuticals Inc | $8,141,000 | -15.4% | 44,000 | -24.1% | 2.36% | -16.2% |
| BIIB | Sell | Biogen IDEC Inc | $7,298,000 | -23.9% | 21,500 | -25.9% | 2.12% | -24.7% |
| RAD | Sell | Rite Aid Corp | $5,903,000 | +9.1% | 785,000 | -29.8% | 1.71% | +8.0% |
| F113PS | Sell | Covidien Plc | $5,830,000 | -11.3% | 57,000 | -25.0% | 1.69% | -12.2% |
| BMRN | Sell | BioMarin Pharmaceutical Inc | $5,514,000 | -16.9% | 61,000 | -33.7% | 1.60% | -17.8% |
| ACAD | Sell | Acadia Pharmaceuticals Inc | $5,239,000 | -3.4% | 165,000 | -24.7% | 1.52% | -4.3% |
| VRTX | Sell | Vertex Pharmaceuticals Inc | $4,514,000 | -6.5% | 38,000 | -11.6% | 1.31% | -7.5% |
| SLXP | Sell | Salix Pharmaceutical Ltd | $4,368,000 | -48.2% | 38,000 | -29.6% | 1.27% | -48.7% |
| CLDN | Sell | Celladon Corp | $3,828,000 | +42.6% | 196,000 | -23.6% | 1.11% | +41.2% |
| NKTR | Sell | Nektar Therapeutics | $3,689,000 | -39.8% | 238,000 | -53.1% | 1.07% | -40.4% |
| ABC | Sell | AmerisourceBergen Corp | $3,606,000 | -6.7% | 40,000 | -20.0% | 1.04% | -7.7% |
| DXCM | Sell | Dexcom Inc | $3,523,000 | -16.9% | 64,000 | -39.6% | 1.02% | -17.7% |
| CYH | Sell | Community Health Syst Inc | $3,451,000 | -20.3% | 64,000 | -19.0% | 1.00% | -21.1% |
| MCK | Sell | McKesson Corp | $3,321,000 | -22.5% | 16,000 | -27.3% | 0.96% | -23.2% |
| INCY | Sell | Incyte Corp Ltd | $3,217,000 | -38.7% | 44,000 | -58.9% | 0.93% | -39.4% |
| P103PS | Sell | NPS Pharmaceuticals Inc | $3,184,000 | -45.3% | 89,000 | -60.3% | 0.92% | -45.9% |
| HCA | Sell | HCA Holdings Inc | $3,009,000 | -26.4% | 41,000 | -29.3% | 0.87% | -27.2% |
| THOR | Sell | Thoratec Corp | $2,986,000 | -16.5% | 92,000 | -31.2% | 0.86% | -17.4% |
| ELGX | Sell | Endologix Inc | $2,966,000 | +39.9% | 194,000 | -3.0% | 0.86% | +38.5% |
| CNC | Sell | Centene Corp | $2,908,000 | +17.2% | 28,000 | -6.7% | 0.84% | +16.1% |
| ABMD | Sell | Abiomed Inc | $2,778,000 | -7.3% | 73,000 | -39.5% | 0.80% | -8.3% |
| TMO | Sell | Thermo Fisher Scientific Inc | $2,756,000 | -53.8% | 22,000 | -55.1% | 0.80% | -54.2% |
| ARIA | Sell | Ariad Pharmaceuticals Inc | $2,727,000 | +19.4% | 397,000 | -6.1% | 0.79% | +18.1% |
| MGNX | Sell | Macrogenics Inc | $2,630,000 | +48.0% | 75,000 | -11.8% | 0.76% | +46.5% |
| STJ | Sell | St Jude Medical Inc | $2,601,000 | -24.1% | 40,000 | -29.8% | 0.75% | -24.8% |
| ISIS | Sell | Isis Pharmaceuticals Inc | $2,593,000 | +15.1% | 42,000 | -27.6% | 0.75% | +14.1% |
| MDT | Sell | Medtronic Inc | $2,527,000 | -63.2% | 35,000 | -73.8% | 0.73% | -63.6% |
| AET | Sell | Aetna Inc | $2,487,000 | -12.3% | 28,000 | -20.0% | 0.72% | -13.1% |
| CERN | Sell | Cerner Corp | $2,457,000 | +3.1% | 38,000 | -5.0% | 0.71% | +2.0% |
| EW | Sell | Edwards Lifesciences Corp | $2,420,000 | +18.5% | 19,000 | -5.0% | 0.70% | +17.2% |
| PODD | Sell | Insulet Corp | $2,395,000 | +3.3% | 52,000 | -17.3% | 0.69% | +2.2% |
| OREX | Sell | Orexigen Therapeutics Inc | $2,273,000 | +8.0% | 375,000 | -24.1% | 0.66% | +7.0% |
| PCYC | Sell | Pharmacyclics Inc | $2,262,000 | -49.3% | 18,500 | -51.3% | 0.66% | -49.8% |
| CYBX | Sell | Cyberonics Inc | $2,227,000 | +1.2% | 40,000 | -7.0% | 0.64% | +0.2% |
| DVAX | Sell | Dynavax Technologies Corp | $2,071,000 | +17.9% | 122,835 | -90.0% | 0.60% | +16.7% |
| KERX | Sell | Keryx Biopharmaceuticals Inc | $1,279,000 | -31.6% | 90,424 | -33.5% | 0.37% | -32.3% |
| ECYT | Exit | Endocyte Inc | $0 | – | -49,297 | -100.0% | -0.09% | – |
| SRNE | Exit | Sorrento Therapeutics Inc | $0 | – | -72,535 | -100.0% | -0.10% | – |
| 5100PS | Exit | Volcano Corp | $0 | – | -44,221 | -100.0% | -0.14% | – |
| EXEL | Exit | Exelixis Inc | $0 | – | -500,000 | -100.0% | -0.22% | – |
| SNSS | Exit | Sunesis Pharmaceuticals Inc | $0 | – | -201,171 | -100.0% | -0.42% | – |
| SYK | Exit | Stryker Corp | $0 | – | -21,000 | -100.0% | -0.50% | – |
| AFL | Exit | Aflac Inc | $0 | – | -32,000 | -100.0% | -0.55% | – |
| NUVA | Exit | NuVasive Inc | $0 | – | -54,000 | -100.0% | -0.55% | – |
| IMGN | Exit | ImmunoGen Inc | $0 | – | -180,000 | -100.0% | -0.56% | – |
| INFI | Exit | Infinity Pharm Inc | $0 | – | -148,000 | -100.0% | -0.58% | – |
| CI | Exit | Cigna Corp | $0 | – | -22,000 | -100.0% | -0.58% | – |
| HPTX | Exit | Hyperion Therapeutics Inc | $0 | – | -80,369 | -100.0% | -0.59% | – |
| CFN | Exit | CareFusion Corp | $0 | – | -45,000 | -100.0% | -0.60% | – |
| PRXL | Exit | Parexel Intl Corp | $0 | – | -34,000 | -100.0% | -0.63% | – |
| AEGR | Exit | Aegerion Pharmaceuticals Inc | $0 | – | -65,000 | -100.0% | -0.64% | – |
| MD | Exit | Mednax Inc | $0 | – | -44,000 | -100.0% | -0.71% | – |
| BCR | Exit | CR Bard Inc | $0 | – | -17,000 | -100.0% | -0.71% | – |
| BSX | Exit | Boston Scientific Corp | $0 | – | -214,000 | -100.0% | -0.74% | – |
| ESRX | Exit | Express Scripts Hg Co | $0 | – | -39,000 | -100.0% | -0.81% | – |
| Exit | Allscripts Healthcare So Inc | $0 | – | -210,000 | -100.0% | -0.82% | – | |
| MASI | Exit | Masimo Corp | $0 | – | -135,000 | -100.0% | -0.84% | – |
| AGN | Exit | Allergan Inc | $0 | – | -16,500 | -100.0% | -0.86% | – |
| TEVA | Exit | Teva Pharma Ind Ltd ADR repr 1 Share | $0 | – | -59,000 | -100.0% | -0.93% | – |
| CTRX | Exit | Catamaran Corp | $0 | – | -93,000 | -100.0% | -1.15% | – |
| V107SC | Exit | WellPoint Inc | $0 | – | -35,000 | -100.0% | -1.23% | – |
| UHS | Exit | Universal Health Services Inc B | $0 | – | -98,700 | -100.0% | -3.02% | – |
| Exit | Johnson & Johnsoncall | $0 | – | -140,000 | -100.0% | -4.37% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-02-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.